Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response

Autor(es)

Martins-de-Souza, Daniel ^{[1, 2]} ; Solaria, Fiorella A. ^[3] ; Guest, Paul C. ^[1] ; Zahedi, Rene P. ^[3] ; Steiner, Johann ^{[4, 5]}

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Lab Neuroprote, Campinas, SP - Brazil

^[2] UNICAMPs, Neurobiol Ctr, Campinas, SP - Brazil

^[3] Leibniz Inst Analyt Wissensch ISAS, Dortmund - Germany

^[4] Ctr Behav Brain Sci, Magdeburg - Germany

^[5] Univ Magdeburg, Dept Psychiat & Psychotherapy, Magdeburg - Germany

• Tipo de documento: Artigo Científico
• Fonte: NPJ SCHIZOPHRENIA; v. 1, 2015.
• Citações Web of Science: 6

Resumo

Proteomics is a valuable tool to unravel molecular mechanisms involved in human disorders. Considering the mediocre effectiveness of antipsychotics, which are the main class of drug used to treat schizophrenia, we analyzed a cohort of 58 schizophrenia patients who had blood collected before and after 6 weeks of antipsychotic treatment using a shotgun mass spectrometry proteomic profiling approach. Our aim was to unravel molecular pathways involved with an effective drug response. The results showed that all patients had essentially the same biochemical pathways triggered Independent of the antipsychotic response outcome. However, we observed that these pathways were regulated in different directions in blood samples from those who responded well to antipsychotics, compared with those who had a poorer outcome. These data are novel, timely and may help to guide new research efforts in the design of new treatments or medications for schizophrenia based on biologically relevant pathways. (AU)

• Processo FAPESP: 14/10068-4 - EMU concedido no processo 13/08711-3: espectrômetro de massas Waters SYNAPT G2-Si HDMs + nanoACQUITY UPLC
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 13/25702-8 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Bolsas no Brasil - Jovens Pesquisadores
• Processo FAPESP: 13/08711-3 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
• Beneficiário: Daniel Martins-de-Souza
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores